Total reported value
$759.2M
Reporting period: 2026-03-31 · Number of holdings: 54
Opaleye Management Inc. disclosed 54 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $759.2M and a quarterly turnover rate of 47.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "O"
Trim HROW
-27.5% -$91.5M
Add ETON
0.0% $22.2M
Add M8694L137
+10.2% $20.5M
Add URGN
+432.7% $19.4M
Add MGTX
+443.2% $15.3M
Add CATX
+294.7% $14.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow INC | Stock-Other | 13.15% | -12.10% | -27.47% | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 11.70% | +0.49% | +4.52% | |
| 3 | ETON | Eton Pharmaceuticals INC | Stock-Other | 9.30% | +2.92% | — | |
| 4 | ✓ | Stock-Other | 5.22% | +2.70% | +10.20% | ||
| 5 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 4.65% | — | -62.73% | |
| 6 | APGE | Apogee Therapeutics INC | Stock-Other | 4.32% | +0.45% | +0.45% | |
| 7 | IRON | Disc Medicine INC | Stock-Other | 3.55% | +1.45% | +110.50% | |
| 8 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.39% | +2.56% | +432.74% | |
| 9 | ✓ | Crescent Biopharma INC. | Stock-Other | 3.18% | +1.34% | +11.40% | |
| 10 | STOK | Stoke Therapeutics INC | Stock-Other | 3.00% | +0.09% | +0.72% | |
| 11 | CATX | Perspective Therapeutics INC | Stock-Other | 2.57% | +1.91% | +294.68% | |
| 12 | RZLT | Rezolute INC | Stock-Other | 2.53% | +0.57% | +0.20% | |
| 13 | MGTX | MeiraGTx Holdings plc | Stock-Other | 2.42% | +2.01% | +443.25% | |
| 14 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 2.34% | +0.24% | — | |
| 15 | SNWV | Sanuwave Health INC | Stock-Other | 2.23% | -1.63% | — | |
| 16 | EWTX | Edgewise Therapeutics INC | Stock-Other | 2.07% | +0.43% | — | |
| 17 | ACOG | Alpha Cognition INC | Stock-Other | 1.85% | +0.07% | +23.72% | |
| 18 | ANNX | Annexon INC | Stock-Other | 1.70% | — | -10.32% | |
| 19 | ALMS | Alumis INC | Stock-Other | 1.60% | +0.91% | +2.80% | |
| 20 | CDXS | Codexis INC | Stock-Other | 1.46% | — | -0.07% | |
| 21 | PTGX | Protagonist Therapeutics INC | Stock-Other | 1.39% | +0.18% | -4.76% | |
| 22 | RVMD | Revolution Medicines INC | Stock-Healthcare | 1.28% | +0.23% | — | |
| 23 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.24% | +0.21% | +2.53% | |
| 24 | QTTB | Q32 Bio INC | Stock-Other | 1.06% | +0.97% | +488.77% | |
| 25 | MBX | Mbx Biosciences INC | Stock-Other | 1.02% | — | — | |
| 26 | RLMD | Relmada Therapeutics INC | Stock-Other | 0.86% | +0.26% | — | |
| 27 | CGON | Cg Oncology INC | Stock-Other | 0.85% | -1.40% | -76.88% | |
| 28 | JBIO | Jade Biosciences INC | Stock-Other | 0.79% | -0.08% | — | |
| 29 | OCUL | Ocular Therapeutix INC | Stock-Other | 0.67% | -1.88% | -62.38% | |
| 30 | AH30 | Assertio Holdings INC | Stock-Other | 0.67% | +0.67% | NEW | |
| 31 | EDIT | Editas Medicine INC | Stock-Other | 0.63% | +0.63% | NEW | |
| 32 | STRO | Sutro Biopharma INC | Stock-Other | 0.63% | +0.34% | — | |
| 33 | DERM | Journey Medical CORP | Stock-Other | 0.59% | -0.40% | -1.54% | |
| 34 | VYGR | Voyager Therapeutics INC | Stock-Other | 0.58% | — | -3.92% | |
| 35 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.54% | — | — | |
| 36 | TECX | Tectonic Therapeutic INC | Stock-Other | 0.50% | -0.09% | -42.72% | |
| 37 | CABA | Cabaletta Bio INC | Stock-Other | 0.49% | +0.23% | +53.33% | |
| 38 | BDSX | Biodesix INC | Stock-Other | 0.45% | +0.45% | NEW | |
| 39 | RCKT | Rocket Pharmaceuticals INC | Stock-Other | 0.45% | — | — | |
| 40 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 0.44% | +0.19% | +0.84% | |
| 41 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.41% | +0.41% | NEW | |
| 42 | FBIO | Fortress Biotech INC | Stock-Other | 0.38% | -0.15% | -4.40% | |
| 43 | IRD | Opus Genetics INC | Stock-Other | 0.30% | — | — | |
| 44 | RIGL | Rigel Pharmaceuticals INC | Stock-Other | 0.25% | -0.15% | — | |
| 45 | AVIR | Atea Pharmaceuticals INC | Stock-Other | 0.23% | +0.15% | +79.41% | |
| 46 | LYEL | Lyell Immunopharma INC | Stock-Other | 0.21% | +0.21% | NEW | |
| 47 | ENTA | Enanta Pharmaceuticals INC | Stock-Other | 0.21% | — | +66.67% | |
| 48 | NXTC | Nextcure INC | Stock-Other | 0.20% | +0.20% | NEW | |
| 49 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.14% | +0.14% | NEW | |
| 50 | ✓ | Perspective Therapeutics INC | Stock-Other | 0.11% | +0.11% | NEW |
Performance for Q3 2026
+45.9%
Performance Last 4 Quarters
+72.7%
Based on 61% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 54 | $759.2M | 48 | |
| 2025-12-31 | 54 | $757.9M | 45 | |
| 2025-09-30 | 43 | $707.3M | 67 | |
| 2025-06-30 | 41 | $494.1M | 0 | |
| 2025-03-31 | 45 | $449.2M | 100 | |
| 2024-12-31 | 39 | $571.4M | 0 | |
| 2024-09-30 | 44 | $599.6M | 0 | |
| 2024-06-30 | 51 | $437.7M | 0 | |
| 2024-03-31 | 52 | $458.9M | 0 | |
| 2023-12-31 | 47 | $376.1M | 0 | |
| 2023-09-30 | 41 | $307.4M | 0 | |
| 2023-06-30 | 47 | $418.1M | 0 | |
| 2023-03-31 | 41 | $333.9M | 0 | |
| 2022-12-31 | 40 | $287.6M | 0 | |
| 2022-09-30 | 42 | $242.1M | 0 | |
| 2022-06-30 | 47 | $221.9M | 0 | |
| 2022-03-31 | 45 | $322.0M | 0 | |
| 2021-12-31 | 39 | $471.5M | 0 | |
| 2021-09-30 | 48 | $535.4M | 0 | |
| 2021-06-30 | 48 | $602.1M | 37 | |
| 2021-03-31 | 58 | $680.8M | 64 | |
| 2020-12-31 | 59 | $765.6M | 60 | |
| 2020-09-30 | 55 | $511.3M | 53 | |
| 2020-06-30 | 48 | $495.2M | 92 | |
| 2020-03-31 | 44 | $377.4M | 82 | |
| 2019-12-31 | 47 | $509.7M | 74 | |
| 2019-09-30 | 49 | $276.5M | 64 | |
| 2019-06-30 | 43 | $328.1M | 62 | |
| 2019-03-31 | 53 | $361.1M | 81 | |
| 2018-12-31 | 47 | $268.0M | 66 | |
| 2018-09-30 | 47 | $393.0M | 37 | |
| 2018-06-30 | 36 | $386.4M | 66 | |
| 2018-03-31 | 38 | $349.7M | 48 | |
| 2017-12-31 | 35 | $312.3M | 56 | |
| 2017-09-30 | 34 | $282.8M | 46 | |
| 2017-06-30 | 41 | $239.4M | 50 | |
| 2017-03-31 | 44 | $200.9M | 63 | |
| 2016-12-31 | 40 | $169.7M | 60 | |
| 2016-09-30 | 44 | $191.1M | 100 | |
| 2016-06-30 | 49 | $149.7M | 84 | 1H03579262957M3023111 |
| 2016-03-31 | 52 | $160.4M | 65 | |
| 2015-12-31 | 53 | $239.2M | 52 | |
| 2015-09-30 | 49 | $203.2M | 55 | |
| 2015-06-30 | 46 | $251.3M | 42 | |
| 2015-03-31 | 37 | $215.4M | 66 | |
| 2014-12-31 | 36 | $197.9M | 65 | |
| 2014-09-30 | 30 | $128.3M | 48 | |
| 2014-06-30 | 27 | $116.0M | 65 | |
| 2014-03-31 | 30 | $135.4M | 94 | |
| 2013-12-31 | 23 | $127.4M | 0 |
Opaleye Management Inc.'s most significant position changes for 2026-03-31: Sold out: Alkermes plc (ALKS); Sold out: Gossamer Bio INC (GOSS); Sold out: Karyopharm Therapeutics INC (KPTI); New buy: Assertio Holdings INC (AH30); New buy: Editas Medicine INC (EDIT).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ETON | Eton Pharmaceuticals INC | +2.9% | — | Unchanged |
| 2 | ✓ | +2.7% | +10.20% | Add | |
| 3 | URGN | UroGen Pharma Ltd. | +2.6% | +432.74% | Add |
| 4 | MGTX | MeiraGTx Holdings plc | +2% | +443.25% | Add |
| 5 | CATX | Perspective Therapeutics INC | +1.9% | +294.68% | Add |
| 6 | IRON | Disc Medicine INC | +1.5% | +110.50% | Add |
| 7 | ✓ | Crescent Biopharma INC. | +1.3% | +11.40% | Add |
| 8 | QTTB | Q32 Bio INC | +1% | +488.77% | Add |
| 9 | ALMS | Alumis INC | +0.9% | +2.80% | Add |
| 10 | RZLT | Rezolute INC | +0.6% | +0.20% | Add |
| 11 | LQDA | Liquidia CORP | +0.5% | +4.52% | Add |
| 12 | APGE | Apogee Therapeutics INC | +0.5% | +0.45% | Add |
| 13 | EWTX | Edgewise Therapeutics INC | +0.4% | — | Unchanged |
| 14 | STRO | Sutro Biopharma INC | +0.3% | — | Unchanged |
| 15 | RLMD | Relmada Therapeutics INC | +0.3% | — | Unchanged |
| 16 | TGTX | Tg Therapeutics INC | +0.2% | — | Unchanged |
| 17 | RVMD | Revolution Medicines INC | +0.2% | — | Unchanged |
| 18 | CABA | Cabaletta Bio INC | +0.2% | +53.33% | Add |
| 19 | XOMA | Xoma Royalty Corporation | +0.2% | +2.53% | Add |
| 20 | ZNTL | Zentalis Pharmaceuticals INC | +0.2% | +0.84% | Add |
| 21 | PTGX | Protagonist Therapeutics INC | +0.2% | -4.76% | Trim |
| 22 | AVIR | Atea Pharmaceuticals INC | +0.2% | +79.41% | Add |
| 23 | STOK | Stoke Therapeutics INC | +0.1% | +0.72% | Add |
| 24 | ACOG | Alpha Cognition INC | +0.1% | +23.72% | Add |
| 25 | JBIO | Jade Biosciences INC | -0.1% | — | Unchanged |
| 26 | TECX | Tectonic Therapeutic INC | -0.1% | -42.72% | Trim |
| 27 | RIGL | Rigel Pharmaceuticals INC | -0.2% | — | Unchanged |
| 28 | FBIO | Fortress Biotech INC | -0.2% | -4.40% | Trim |
| 29 | DERM | Journey Medical CORP | -0.4% | -1.54% | Trim |
| 30 | PLX | Protalix Biotherapeutics INC | -0.5% | -86.28% | Trim |
| 31 | CGON | Cg Oncology INC | -1.4% | -76.88% | Trim |
| 32 | SNWV | Sanuwave Health INC | -1.6% | — | Unchanged |
| 33 | OCUL | Ocular Therapeutix INC | -1.9% | -62.38% | Trim |
| 34 | HROW | Harrow INC | -12.1% | -27.47% | Trim |
| 35 | ALKS | Alkermes plc | — | EXIT | Sold out |
| 36 | GOSS | Gossamer Bio INC | — | EXIT | Sold out |
| 37 | KPTI | Karyopharm Therapeutics INC | — | EXIT | Sold out |
| 38 | AH30 | Assertio Holdings INC | — | NEW | New buy |
| 39 | EDIT | Editas Medicine INC | — | NEW | New buy |
| 40 | BDSX | Biodesix INC | — | NEW | New buy |
| 41 | NTLA | Intellia Therapeutics INC | — | NEW | New buy |
| 42 | ZYME | Zymeworks INC | — | EXIT | Sold out |
| 43 | ✓ | Assertio Holdings INC | — | EXIT | Sold out |
| 44 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 45 | ✓ | — | EXIT | Sold out | |
| 46 | LYEL | Lyell Immunopharma INC | — | NEW | New buy |
| 47 | NXTC | Nextcure INC | — | NEW | New buy |
| 48 | BBIO | Bridgebio Pharma INC | — | EXIT | Sold out |
| 49 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 50 | ✓ | Perspective Therapeutics INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0001766157
Total reported value
$759.2M
271 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001845445
Total reported value
$758.8M
209 stks
2024-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001274196
Total reported value
$758.7M
39 stks
2025-09-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001037353
Total reported value
$4.3M
2 stks
2026-03-31
1 of the top 5 holdings overlap, including Liquidia CORP
CIK 0001058854
Total reported value
$162.9M
41 stks
2026-03-31
1 of the top 5 holdings overlap, including Eton Pharmaceuticals INC
CIK 0001176347
Total reported value
$620.1M
4 stks
2026-03-31
1 of the top 5 holdings overlap, including Rhythm Pharmaceuticals INC